CD34 and acute myeloid leukemia: It is also noteworthy that the combination of ABT-199 and A-1210477, involving exposure to concentrations of each drug documented in Fig. S11 also synergistically induced loss-of-viability in three samples of PD CD34+ AML BPCs (Fig. 5d and S4G).